Genes, chromatin, and breast cancer: An epigenetic tale

Journal of Mammary Gland Biology and Neoplasia

Volumn 6, Issue 2, 2001, Pages 169-182

  Mielnicki, Lawrence M ^a   Asch, Harold L ^a   Asch, Bonnie B ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Breast cancer; Chromatin; DNA methylation; Epigenetics; Gene expression; Histone acetylation

Indexed keywords

ACTIN; BRCA1 PROTEIN; BRCA2 PROTEIN; BUTYRIC ACID; FR 901228; GELSOLIN; HISTONE; HISTONE DEACETYLASE INHIBITOR; PROTEIN P21; RETINOIC ACID; RETINOIC ACID RECEPTOR; STEROID RECEPTOR; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UVOMORULIN; VORINOSTAT; HISTONE DEACETYLASE;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CELL CYCLE; CHROMATIN STRUCTURE; CLINICAL TRIAL; DEACETYLATION; DNA METHYLATION; DNA MODIFICATION; EPIGENETICS; GENE EXPRESSION REGULATION; GENE TARGETING; HOX GENE; HUMAN; LEUKEMIA; MUTATION; NONHUMAN; PROMOTER REGION; SYSTEMATIC REVIEW; TRANSCRIPTION REGULATION; BREAST TUMOR; CHROMATIN; DRUG ANTAGONISM; FEMALE; GENETICS; GENOME; REVIEW;

BREAST NEOPLASMS; CHROMATIN; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME; HISTONE DEACETYLASES; HUMANS; PROMOTER REGIONS (GENETICS);

EID: 0035320252     PISSN: 10833021     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011356623442     Document Type: Article

References (131)

1. P. A. Jones and P. W. Laird (1999). Cancer epigenetics comes of age. Nat. Gene. 21:163-167.
2. R. Sager (1997). Expression genetics in cancer: Shifting the focus from DNA to RNA. Proc. Natl. Acad. Sci. U.S.A. 94:952-955.
3. K. D. Robertson and A.P. Wolffe (2000). DNA methylation in health and disease. Nat. Rev. 1:11-19.
4. Y. Mizumoto, T. Kimura, and R. Ivell (1997). A genomic element within the third intron of the human oxytocin receptor gene may be involved in transcriptional suppression. Mol Cell Endocrinol. 135: 29-138.
5. R. Wicki, C. Franz, F. A. Scholl, C. W. Heizmann, and B. W. Schafr (1997). Repression of the candidate tumor suppressor gene S100A2 in breast cancer is mediated by site-specific hypermethylation. Cell Calcium 22:243-254.
6. S. U. Kass, D. Pruss, and A. P. Wolffe (1997). How does DNA methylation repress transcription? Trends Genet 13:444-449.
7. S. A. Foster, D. J. Wong, M. T. Barrett, and D. A. Galloway (1998). Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol. Cell Biol. 18:1793-1801.
8. S. Hiraguri, T. Godfrey, H. Nakamura, J. Graff, C. Collins, L. Shayesteh, N. Doggett, K. Johnson, M. Wheelock, J. Herman, S. Baylin, D. Pinkel, and J. Gray (1998). Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Res. 58:1972-1977.
9. A. Dobrovic and D. Simpfendorfer (1997). Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res. 57:3347-3350.
10. A. P. Wolffe, F. D. Urnov, and D. Guschin (2000). Corepressor complexes and remodeling chromatin for repression. Biochem. Soc. Trans. 28:379-386.
11. X. Nan, H. H. Ng, C. A. Johnson, C. D. Laherty, B. M. Turner, R. N. Eisenman, and A. Bird (1998). Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex [see comments]. Nature393:386-389.
12. E. Cameron, K. Bachman, S. Myohanen, J. Herman, and S. Baylin (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21: 03-107.
13. P. Jeppesen and B. M. Turner (1993). The inactive X chromosome in female mammals is distinguished by a lack of histone H4 acetylation, a cytogenetic marker for gene expression. Cell 74:281-289.
14. M. S. Bartolomei and S. M. Tilghman (1997). Genomic imprinting in mammals. Ann. Rev. Genet. 31:493-525.
15. J. Zlatanova, P. Caiafa, and K. Van Holde (2000). Linker histone binding and displacement: Versatile mechanism for transcriptional regulation. FASEB J. 14:1697-1704.
16. A. D. Pham and F. Sauer (2000). Ubiquitin-activating/conjugating activity of TAF(II)250, a mediator of activation of gene expression in Drosophila. Science 289:2357-2360.
17. K. Robzyk, J. Recht, and M. A. Osley (2000). Rad6-dependent ubiquitination of histone H2B in yeast. Science 287:501-504.
18. M. R. Stallcup, D. Chen, S. S. Koh, H. Ma, Y. Lee, H. Li, B. T. Schurter, and D. W. Aswad (2000). Co-operation between protein-acetylating and protein-methylating co-activators in transcriptional activation. Biochem. Soc. Trans. 28:415-418.
19. C. VanLint, S. Emiliani, and E. Verdin (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Exp. 5:245-253.
20. M. Frommer, L. E. McDonald, D. S. Millar, C. M. Collis, F. Watt, G. W. Grigg, P. L. Molloy, and C. L. Paul (1992). A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. U.S.A. 89: 827-1831.
21. J. G. Herman, A. Merlo, L. Mao, R. G. Lapidus, J-P. J. Issa, N. E. Davidson, D. Sidransky, and S. B. Baylin (1995). Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 55: 525-4530.
22. G. P. Delcuve and J. R. Davie (1987). DNA methylation pattern and restriction endonuclease accessibility in chromatin of a germ-line specific gene, the rainbow trout protamine gene. Nucleic Acids Res. 15:3385-3396.
23. F. M. Ausubel, R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl (Eds.), Current Protocols in Molecular Biology John Wiley Inc., New York.
24. M. Braunstein, R. E. Sobel, C. D. Allis, B. M. Turner, and J. R. Broach (1996). Efficient transcriptional silencing in Saccharomyces cerevisiae requires a heterochromatin histone acetylation pattern. Mol. Cell Biol. 16:4349-4356.
25. B. A. Boggs, B. Connors, R. E. Sobel, A. C. Chinault, and C. D. Allis (1996). Reduced levels of histone h3 acetylation on the inactive X chromosome in human females. Chromosoma 105(5):303-309.
26. D. A. White, N. D. Belyaev, and B. M. Turner (1999). Preparation of site-specific antibodies to acetylated histones. Methods (Duluth). 19(3):417-424.
27. M. H. Kuo and C. D. Allis (1999). In vivo cross-linking and immunoprecipitation for studying dynamic protein: DNA associations in chromatin environment. Methods (Duluth). 19(3):425-433.
28. D. A. Bochar, L. Wang, H. Beniya, A. Kinev, Y. Xue, W. S. Lane, W. Wang, F. Kashanchi, and R. Shiekhattar (2000). BRCA1 is associated with a human SWI/SNF-related complex: Linking chromatin remodeling to breast cancer. Cell 102:257-265.
29. P. Cheung, K. G. Tanner, W. L. Cheung, P. Sassone-Corsi, J. M. Denu, and C. D. Allis (2000). Synergistic coupling of histone H3 phosphorylation and acetylation in response to epidermal growth factor stimulation. Mol. Cell. 5:905-915.
30. A. L. Clayton, S. Rose, M. J. Barratt, and L. C. Mahadevan (2000). Phosphoacetylation of histone H3 on c-fos- and c- jun associated nucleosomes upon gene activation. EMBO J. 19: 714-3726.
31. D. T. Bishop (1999). BRCA1 and BRCA2 and breast cancer incidence: A review. Ann. Oncol. 10:113-119.
32. B. Arver, Q. Du, J. Chen, L. Luo, and A. Lindblom (2000). Hereditary breast cancer: A review. Semin Cancer Biol. 10:271-288.
33. M. E. Thompson, R. A. Jensen, P. S. Obermiller, D. L. Page, and J. T. Holt (1995). Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet. 9:444-450.
34. C. A. Wilson, L. Ramos, M. R. Villasenor, K. H. Anders, M. F. Press, K. Clarke, B. Karlan, J. J. Chen, R. Scully, D. Livingston, R. H. Zuch, M. H. Kanter, S. Cohen, F. J. Calzone, and D. J. Slamon (1999). Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet. 21:236-240.
35. F. Magdinier, L. M. Billard, G. Wittmann, L. Frappart, M. Benchaib, G. M. Lenoir, J. F. Guerin, and R. Dante (2000). Regional methylation of the 5′ end CpG island of BRCA1 is associated with reduced gene expression in human somatic cells. FASEB J. 14:1585-1594.
36. J. C. Rice and B. W. Futscher (2000). Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res. 28:3233-3239.
37. J. C. Rice, K. S. Massey-Brown, and B. W. Futscher (1998). Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 17: 807-1812.
38. J. C. Rice, H. Ozcelik, P. Maxeiner, I. Andrulis, and B. W. Futscher (2000). Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21:1761-1765.
39. T. Bianco, G. Chenevix-Trench, D. C. Walsh, J. E. Cooper, and A. Dobrovic (2000). Tumor-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21:147-151.
40. H. Ozcelik, M. D. To, J. Couture, S. B. Bull, and I. L. Andrulis (1998). Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers. Int. J. Cancer 77:1-6.
41. C. F. Xu, J. A. Chambers, and E. Solomon (1997). Complexregulation of the BRCA1 gene. J. Biol. Chem. 272:20994-20997.
42. S. Thakur C. M. Croce (1999). Positive regulation of the BRCA1 promoter. J. Biol. Chem. 274:8837-8843.
43. V. Budhram-Mahadeo, D. Ndisang, T. Ward, B. L. Weber, and D. S. Latchman (1999). The Brn-3b POU family transcription factor represses expression of the BRCA-1 anti-oncogene in breast cancer cells. Oncogene 18:6684-6691.
44. D. S. Latchman (1999). POU family transcription factors in the nervous system. J. Cell Physiol. 179:126-133.
45. C. X. Deng and S. G. Brodie (2000). Roles of BRCA1 and its interacting proteins. Bioessays 22:728-737.
46. G. M. Pao, R. Janknecht, H. Ruffner, T. Hunter, and I. M. Verma (2000). CBP/p300 interact with and function as transcriptional coactivators of BRCA1. Proc. Natl. Acad. Sci. U.S.A. 97:1020-1025.
47. Y. Wang, D. Cortez, P. Yazdi, N. Neff, S. J. Elledge, and J. Qin (2000). BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev. 14:927-939.
48. A. Katsama, G. Sourvinos, G. Zachos, and D. A. Spandidos (2000). Allelic loss at the BRCA1, BRCA2, and TP53 loci in human sporadic breast carcinoma. Cancer Lett. 150:165-170.
49. C. Rauh-Adelmann, K. M. Lau, N. Sabeti, J. P. Long, S. C. Mok, and S. M. Ho (2000). Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol. Carcinog. 28: 36-246.
50. H. Siddique, J-P. Zou, V. N. Rao, and E. S. P. Reddy (1998). The BRCA2 is a histone acetyltransferase (HAT). Oncogene 16:2283-2285.
51. F. Fuks, J. Milner, and T. Kouzarides (1998). BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17: 531-2534.
52. T. Sugimura and T. Ushijima (2000). Genetic and epigenetic alterations in carcinogenesis. Mutat. Res. 462:235-246.
53. R. L. Momparler and V. Bovenzi (2000). DNA methylation and cancer. J. Cell Physiol. 183:145-154.
54. I. McEwan (2000). Steroid receptor co-activators and the remodeling of chromatin. Biochem. Soci. Trans. 28:369-373.
55. J. D. Love, J. T. Gooch, L. Nagy, V. K. Chatterjee, and J. W. Schwabe (2000). Transcriptional repression by nuclear receptors: Mechanisms and role in disease. Biochem. Soc. Trans. 28:390-396.
56. 1-phase progression. Genes Dev. 13: 501-1512.
57. J. Tsihlias, L. Kapusta, and J. Slingerland (1999). The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Ann. Rev. Med. 50:401-423.
58. J. F. Costello, M. S. Berger, H. J. S. Huang, and W. K. Cavenee (1996). Silencing of p16/cdkn2 expression in human gliomas by methylation and chromatin condensation. Cancer Res. 56(10):2405-2410.
59. WAF1 promoter region. Cancer Res. 60:3290-3298.
60. WAF/Cip1 by distinct mechanisms. J. Biol. Chem. 274:24250-24256.
61. (WAF1/CIP1/sdi1). J. Biol. Chem. 275: 353-6359.
62. (INK4a). Mol. Cell. Biol. 19:3916-3928.
63. L. C. Sambucetti, D. D. Fischer, S. Zabludoff, P. O. Kwon, H. Chamberlin, N. Trogani, H. Xu, and D. Cohen (1999). Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J. Biol. Chem. 274:34940-34947.
64. waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J. Cell. Biochem. 73: 91-302.
65. WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U.S.A. 97:10014-10019.
66. T. C. Wang, R. D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E. V. Schmidt (1994). Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671.
67. C. Dickson, V. Fantl, C. Gillett, S. Brookes, J. Bartek, R. Smith, C. Fisher, D. Barnes, and G. Peters (1995). Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett. 90:43-50.
68. F. Lallemand, D. Courilleau, M. Sabbah, G. Redeuilh, and J. Mester (1996). Direct inhibition of the expression of cyclin D1 gene by sodium butyrate. Biochem. Biophys. Res. Comm. 229:163-169.
69. B. M. Ghadimi, J. Behrens, I. Hoffmann, W. Haensch, W. Birchmeier, and P. M. Schlag (1999). Immunohistological analysis of E-cadherin, α-, β-, γ-catenin expression in colorectal cancer: Implications for cell adhesion and signaling. Eur. J. Cancer 35:60-65.
70. W. Zschiesche, I. Schonborn, J. Behrens, K. Herrenknecht, F. Hartveit, P. Lilleng, and W. Birchmeier (1997). Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res. 17:561-567.
71. I. R. Beavon (2000). The E-cadherin-catenin complex in tumor metastasis. Structure, function and regulation. Eur. J. Cancer 36:1607-1620.
72. J. R. Graff, J. G. Herman, R. G. Lapidus, H. Chopra, R. Xu, D. F. Jarrard, W. B. Isaacs, P. M. Pitha, N. E. Davidson, and S. B. Baylin (1995). E-Cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res. 55: 195-5199.
73. S. J. Nass, J. G. Herman, E. Gabrielson, P. W. Iversen, F. F. Parl, N. E. Davidson, and J. R. Graff (2000). Aberrant methylation of the estrogen receptor and E-cadherin 5′ CpG islands increases with malignant progression in human breast cancer. Cancer Res. 60: 346-4348.
74. J. R. Graff, E. Gabrielson, H. Fujii, S. B. Baylin, and J. G. Herman (2000). Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J. Biol. Chem. 275: 727-2732.
75. A. Ben-Ze'ev (1985). The cytoskeleton in cancer cells. Biochim. Biophys. Acta. 780:197-212.
76. P. A. Janmey and C. Chaponnier (1995). Medical aspects of the actin cytoskeleton. Curr. Opin. Cell Biol. 7:111-117.
77. H. K. Lee, D. Driscoll, H. Asch, B. Asch, and P. J. Zhang (1999). Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate. Prostate 40:14-19.
78. H. L. Asch, K. Head, Y. Dong, F. Natoli, J. S. Winston, J. S. Connolly, and B. B. Asch (1996). Widespread loss of gelsolin in breast cancers of humans, mice, and rats. Cancer Res. 56:4841-4845.
79. Y. Hoshikawa, H. J. Kwon, M. Yoshida, S. Horinouchi, and T. Beppu (1994). Trichostatin A induces morphological changes and gelolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exper. Cell Res. 214:189-197.
80. L. M. Mielnicki, A. M. Ying, K. L. Head, H. L. Asch, and B. B. Asch (1999). Epigenetic regulation of gelsolin expression in human breast cancer cells. Experi. Cell Res. 249:161-176.
81. M. Hendricks and H. Weintraub (1981). Tropomyosin is decreased in transformed cells. Proc. Natl. Acad. Sci. U.S.A. 78: 633-5637.
82. B. Bhattacharya, G. L. Prasad, E. M. Valverius, D. S. Salomon, and H. L. Cooper (1990). Tropomyosins of human mammary epithelial cells: Consistent defects of expression in mammary carcinoma cell lines. Cancer Res. 50:2105-2112.
83. S. J. Nass and R. B. Dickson (1997). Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res. Treat. 44:1-22.
84. A. Scorilas, T. Trangas, J. Yotis, C. Pateras, and M. Talieri (1999). Determination of c-myc amplification and overexpression in breast cancer patients: Evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis. Brit. J. Cancer 81:1385-1391.
85. P. M. Siegel, W. R. Hardy, and W. J. Muller (2000). Mammary gland neoplasia: Insights from transgenic mouse models. Bioessays 22:554-563.
86. M. Zajac-Kaye, N. Ben-Baruch, E. Kastanos, F. J. Kaye, and C. Allegra (2000). Induction of Myc-intron-binding polypeptides MIBP1 and RFX1 during retinoic acid-mediated differentiation of haemopoietic cells. Biochem. J. 345(Pt 3): 535-541.
87. T. J. Barrett, N. P. Sandhu, A. J. Tomlinson, L. M. Benson, M. Subramaniam, S. Naylor, and T. C. Spelsberg (2000). Interactions of the nuclear matrix-associated steroid receptor binding factor with its DNA binding element in the c-myc gene promoter. Biochemistry 39:753-762.
88. E. Rabizadeh, M. Shaklai, A. Nudelman, L. Eisenbach, and A. Rephaeli (1993). Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug. FEBS Lett. 328:225-229.
89. C. VanLint, S. Emiliani, and E. Verdin (1996). The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Exp. 5:245-253.
90. A. Veraksa, M. Del Campo, and W. McGinnis (2000). Developmental patterning genes and their conserved functions: From model organisms to humans. Mol. Genet. Metab. 69:85-100.
91. C. Cillo, A. Faiella, M. Cantile, and E. Boncinelli (1999). Homeobox genes and cancer. Exp. Cell. Res. 248:1-9.
92. J. Aubin, M. Lemieux, M. Tremblay, R. R. Behringer, and L. Jeannotte (1998). Transcriptional interferences at the Hoxa4/Hoxa5 locus: Importance of correct Hoxa5 expression for the proper specification of the axial skeleton. Dev. Dynam. 212:141-156.
93. V. Raman, S. A. Martensen, D. Reisman, E. Evron, W. F. Odenwald, E. Jaffee, J. Marks, and S. Sukumar (2000). Compromized HOXA5 function can limit p53 expression in human breast tumors. Nature 405: 74-978.
94. M. P. de Caestecker, E. Piek, and A. B. Roberts (2000). Role of transforming growth factor-β signaling in cancer. J. Natl. Cancer Inst. 92:1388-1402.
95. H. Gobbi, W. D. Dupont, J. F. Simpson, W. D. Plummer, Jr., P. A. Schuyler, S. J. Olson, C. L. Arteaga, and D. L. Page (1999). Transforming growth factor-β and breast cancer risk in women with mammary epithelial hyperplasia. J. Natl. Cancer Inst. 91:2096-2101.
96. W. J. Gullick (1991). Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br. Med. Bull. 47:87-98.
97. Y. H. Xu, N. Richert, S. Ito, G. T. Merlino, and I. Pastan (1984). Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines. Proc. Natl. Acad. Sci. U.S.A. 81:7308-7312.
98. G. T. Merlino, S. Ishii, J. Whang-Peng, T. Knutsen, Y. H. Xu, A. J. Clark, R. H. Stratton, R. K. Wilson, D. P. Ma, B. A. Roe, J. H. Hunts, N. Shimizu, and I. Pastan (1985). Structure and localization of genes encoding aberrant and normal epidermal growth factor receptor RNAs from A431 human carcinoma cells. Mol. Cell. Biol. 5: 722-1734.
99. S. A. Chrysogelos (1993). Chromatin structure of the EGFR gene suggests a role for intron 1 sequences in its regulation in breast cancer cells. Nucleic Acids Res. 21:5736-5741.
100. F. Gebhardt, H. Burger, and B. Brandt (2000). Modulation of EGFR gene transcription by a polymorphic repetitive sequence - a link between genetics and epigenetics. Int. J. Biol. Markers 15:105-110.
101. J. A. Foekens, W. L. van Putten, H. Portengen, H. Y. de Koning, B. Thirion, J. Alexieva-Figusch, and J. G. Klijn (1993). Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: Multivariate analysis. J. Clin. Oncol. 11:899-908.
102. C. Giamarchi, M. Solanas, C. Chailleux, P. Augereau, F. Vignon, H. Rochefort, and H. Richard-Foy (1999). Chromatin structure of the regulatory regions of pS2 and cathepsin D genes in hormone-dependent and -independent breast cancer cell lines. Oncogene 18: 33-541.
103. V. Martin, S. Ribieras, X. G. Song-Wang, Y. Lasne, L. Frappart, M. C. Rio, and R. Dante (1997). Involvement of DNA methylation in the control of the expression of an estrogen-induced breast-cancer-associated protein (pS2) in human breast cancers. J. Cell Biochem. 65:95-106.
104. H. Rochefort (1990). Cathepsin D in breast cancer. Breast Cancer Res. Treat. 16:3-13.
105. V. Cavailles, P. Augereau, and H. Rochefort (1993). Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 90:203-207.
106. C. L. Sommers, J. M. Skerker, S. A. Chrysogelos, M. Bosseler, and E. P. Gelmann (1994). Regulation of vimentin gene transcription in human breast cancer cell lines. Cell Growth Differ. 5:839-846.
107. A. G. Knudson, Jr., H. W. Hethcote, and B. W. Brown (1975). Mutation and childhood cancer: A probabilistic model for the incidence of retinoblastoma. Proc. Natl. Acad. Sci. U.S.A. 72:5116-5120.
108. T. L. Butler, P. H. Kay, and P. F. Jacobsen (2000). Hypomethylation of cytosine 5-methyltransferase in human neoplasms. Anticancer Res. 20:1435-1438.
109. S. A. Gayther, S. J. Batley, L. Linger, A. Bannister, K. Thorpe, S. F. Chin, Y. Daigo, P. Russell, A. Wilson, H. M. Sowter, J. D. Delhanty, B. A. Ponder, T. Kouzarides, and C. Caldas (2000). Mutations truncating the EP300 acetylase in human cancers. Nat. Genet. 24:300-303.
110. A. C. Phillips and K. H. Vousden (2000). Acetyltransferases and tumor suppression. Brit. Cancer. Res. 2:244-246.
111. R. P. Warrell, Jr., L-Z. He, V. Richon, E. Calleja, and P. P. Pandolfi (1998). Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90:1621-1625.
112. E. E. Cameron, K. E. Bachman, S. Myohanen, J. G. Herman, and S. B. Baylin (1999). Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21:103-107.
113. P. R. Gibson (2000). The intracellular target of butyrate's actions: HDAC or HDONT? [comment]. Gut 46:447-448.
114. V. M. Richon, S. Emiliani, E. Verdin, Y. Webb, R. Breslow, R. A. Rifkind, and P. A. Marks (1998). A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. U.S.A. 95:3003-3007.
115. J. Kruh (1982). Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol. Cell Biochem. 42:65-82.
116. R. H. Charollais, C. Buquet, and J. Mester (1990). Butyrate blocks the accumulation of CDC2 mRNA in late G1 phase but inhibits both the early and late G1 progression in chemically transformed mouse fibroblasts BP-A31. J. Cell Physiol. 145:46-52.
117. R. Gope and M. L. Gope (1993). Effect of sodium butyrate on the expression of retinoblastoma (RB1) and p53 gene and phosphorylation of retinoblastoma protein in human colon tumor cell line HT29. Cell. Mol. Biol. 39:589-597.
118. T. Tsutsumi, A. Ido, K. Nakao, K. Hamasaki, Y. Kato, A. Ohtsuru, K. Nakata, T. Tamaoki, and S. Nagataki (1994). Reciprocal regulation of α-fetoprotein and albumin gene expression by butyrate in human hepatoma cells. Gastroenterology 107:499-504.
119. D. Coradini, A. Biffi, A. Costa, C. Pellizzaro, E. Pirronello, and G. Di Fronzo (1997). Effect of sodium butyrate on human breast cancer cell lines. Cell Prolif. 30:149-159.
120. J. A. McBain, A. Eastman, C. S. Nobel, and G. C. Mueller (1997). Apoptosis death in adenocarcinoma cell lines induced by butyrate and other histone deacetylase inhibitors. Biochem. Pharmacol. 53: 357-1368.
121. S. Y. Archer and R. A. Hodin (1999). Histone acetylation and cancer. Curr. Opin. Genet. Dev. 9:171-174.
122. (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc. Natl. Acad. Sci. U.S.A. 95:6791-6796.
123. A. Thibault, M. R. Cooper, W. D. Figg, D. J. Venzon, A. O. Sartor, A. C. Tompkins, M. S. Weinberger, D. J. Headlee, N. A. McCall, and D. Samid (1994). A phase I and pharmacokinetic study of intraveneous phenylacetate in patients with cancer. Cancer Res. 54: 690-1694.
124. R. J. Lin, L. Nagy, S. Inoue, W. Shao, W. H. Miller, Jr., and R. M. Evans (1998). Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814.
125. L. A. Cohen, S. Amin, P. A. Marks, R. A. Rifkind, D. Desai, and V. M. Richon (1999). Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. 19: 999-5005.
126. H. Ueda, H. Nakajima, Y. Hori, T. Fujita, M. Nishimura, T. Goto, and M. Okuhara (1994). FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. (Tokyo) 47:301-310.
127. G. Rajgolikar, K. K. Chan, and H. C. Wang (1998). Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res. Treat. 51:29-38.
128. H. Ueda, T. Manda, S. Matsumoto, S. Mukumoto, F. Nishigaki, I. Kawamura, and K. Shimomura (1994). FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. (Tokyo) 47:315-323.
129. J. Byrd, C. Shinn, R. Ravi, C. Willis, J. Waselenko, I. Flinn, N. Dawson, and M. Grever (1999). Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood 94:1401-1408.
130. K. Chan, R. Bakhtiar, and C. Jiang (1997). Depsipeptide (FR901228, NSC-630176) pharmacokinetics in the rat by LC/MS/MS. Invest. New Drugs 15:195-206.
131. J. G. Page, L. E. Rodman, J. E. Heath, J. E. Tomaszewski, and A. C. Smith (1995). Effect of infusion rat on the toxicity of depsipeptide (NSC-630176) in beagle dogs. Proc. Amer. Assoc. Cancer Res. 36: 68.